HOOKIPA Pharma Earnings Call Transcripts
Fiscal Year 2024
-
The company is advancing arenavirus-based immunotherapies, with eservivec (HB-200) showing strong phase 2 results in head and neck cancer and aiming for market entry by 2027. Financial resources are focused on this lead program, while partnerships support other pipeline assets.
-
The meeting, held virtually for global access, saw all proposals—including director elections, auditor ratification, an increase in authorized shares, and a reverse stock split—overwhelmingly approved by shareholders. Final results will be reported in SEC filings.
-
HB-200 plus pembrolizumab demonstrated strong efficacy and durability in HPV-16 positive head and neck cancer, especially in the CPS 20+ subgroup, with a pivotal phase II/III trial set to start in Q4 2024. Regulatory alignment and market expansion plans are in place.